CClinicalTrials.gg
Status unknownNCT05052320Updated Sep 24, 2021

Audiological Assessment of Recovered Covid 19 Subjects.

An observational study in Covid 19, sponsored by Assiut University. Status unknown. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-09-24.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To assess the audiological profile in recovered covid 19 subjects in comparison with control group.

Read the detailed description

The outbreak of novel Severe Acute Respiratory Syndrome Corona virus type 2 (nSARS-CoV-2) infection in Wuhan, China in December 2019 has had impact on the world, resulting in over 2.2 million deaths globally The world envisioned sufferings of high proportions of losses in terms of health,finances and importantly, life.

The common symptoms including fever, cough, fatigue and gastrointestinal disorders have been well documented. Sensorineural hearing loss has been more commonly implicated in these patients although a few have exhibited conductive hearing loss. theViral upper respiratory tract infections have linked to new cases of otitis media. Although There is some controversy regarding the significance of viral species, but the human corona virus has been isolated from middle ear fluid and linked to otitis media in children. Most patients affected are asymptomatic or experience mild symptoms.

Various theories explaining the involvement of the ear following covid infection have been pos tulated, which include immune mediated damage,haematogenous spread, ischaemia theory, inflammation of auditory pathway components, presence of angiotensin converting enzyme receptors (ACE2) receptors in neurons and glial cell.

The hearing loss in COVID-19 could also be the consequence of therapy with chloroquine and hydroxychloroquine, which are part of clinical practice guidelines for COVID-19 treatment in several countries . These drugs are used for the treatment of malaria and some chronic inflammatory diseases as well. It is well known that these medications can induce hearing loss. Ototoxicity of chloroquine and hydroxy- chloroquine is the result of inner ear damage . The recommended dose of these drugs for COVID-19 treatment is higher than for malaria; therefore, ototoxic effect could be higher.Though many vaccines were intro- duced, the disease has hit second and third waves in many countries, elevating the number of infected individuals getting infected .

Some studies reported that the COVID-19 group had significantly poorerhearing thresholds at high frequencies. In addition, the amplitudes of transient evoked otoacoustic emissions ,in two of thesestudies were significantly lower for the COVID-19 group.

02

Conditions studied

  • Covid 19

Browse trials for

03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 70 is below the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Male or female subjects have recovered from covid 19 ..their age from 18_50

Inclusion criteria

  • Age 18_50

Exclusion criteria

Exclusion Criteria:

  1. History of previous ear symptoms, tympanic membrane perforations,ear trauma or ear surgeries
  2. Evidence of systemic illness as Diabetes mellitus, Renal disease, patients received ototoxic drugs.
  3. Evidence of neurologicl or psychiatric disease.
  4. covid 19 Patients not maintaining saturation and requiring O2 support and intensive care unit patient.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • DeviceAudiological assessment

    TO assess audiological profile in recovered covid19 subjects

06

What researchers measure

Primary outcomes

  1. Audiological assessment of recovered covid 19 subjects

    To evaluate the audiological profile of recoveredcovid 19 subjects in comparison with control group

    Time frame: base line

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Fancello V, Hatzopoulos S, Corazzi V, Bianchini C, Skarzynska MB, Pelucchi S, Skarzynski PH, Ciorba A. SARS-CoV-2 (COVID-19) and audio-vestibular disorders. Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211027373. doi: 10.1177/20587384211027373. PubMed 34142589 ↗
  • Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Dec;60(12):935-945. doi: 10.1080/14992027.2021.1896793. Epub 2021 Mar 22. PubMed 33750252 ↗
  • Dharmarajan S, Bharathi MB, Sivapuram K, Prakash BG, Madhan S, Madhu A, Devi GN, Aliya SA, Ramya SB. Hearing Loss-a Camouflaged Manifestation of COVID 19 Infection. Indian J Otolaryngol Head Neck Surg. 2021 Dec;73(4):494-498. doi: 10.1007/s12070-021-02581-1. Epub 2021 May 10. PubMed 33996529 ↗
  • Dusan M, Milan S, Nikola D. COVID-19 caused hearing loss. Eur Arch Otorhinolaryngol. 2022 May;279(5):2363-2372. doi: 10.1007/s00405-021-06951-x. Epub 2021 Jul 8. PubMed 34235578 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05052320
Lead sponsor
Assiut University
Responsible party
Mostafa kamal Mostafa Mohamed (Resident doctor, Assiut University) — Principal investigator
First posted
Sep 22, 2021
Start date
Oct 2021 (estimated)
Primary completion
Oct 2022 (estimated)
Completion
Apr 2023 (estimated)
Last update
Sep 24, 2021

Study contacts

Mostafa Kamal Mostafa
Contact
theking.lovelove93@gmail.com
01111029396
Eman Abdelfatah sayed
Contact
+201007238234

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion